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Abstract
Background: The absolute neutrophil count (ANC) is currently used to assess immune status of  patients on cytotoxic 
therapy. The CD4 lymphocytes have also been shown to be of  importance in protection against opportunistic infections.  In 
people of  African descent a low baseline ANC has been recorded and the currently accepted neutropaenic threshold may 
not be appropriate.  
Objective: This study was aimed at comparing the change in ANC to CD4 lymphocyte count in adult cancer patients fol-
lowing chemotherapy. 
Patients and methods: Eighty chemotherapy-naive patients with various malignancies had their ANC and CD4 lympho-
cyte counts done at days 0 and 12 of  the first cycle of  various chemotherapeutic regimens. The paired sample t-test was done 
to assess the significance between these values. Socio-demographic data was obtained using questionnaires.
Results: ANC and CD4 pre-chemotherapy differed significantly from their post-chemotherapy values (p=0.001) for both 
parameters). The CD4 count showed significant reduction in patients with Non-Hodgkin’s lymphoma (p=0.043), colorectal 
carcinoma (p=0.037) and other malignancies (p=0.030), while the ANC did not. Patients who had received COPP for Hodg-
kin’s lymphoma also had significant CD4 depletion (p=0.037).  
Conclusion: The CD4 lymphocyte count may be a more suitable parameter than ANC, for monitoring immuno-depletion 
in cancer patients on cytotoxic chemotherapy. Further studies are required to validate these findings, especially in the Ne-
groid population.
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Introduction
Cytotoxic chemotherapeutic agents are widely known 
to cause immunosuppression, the extent of  which is 
routinely ascertained by the absolute neutrophil count 
(ANC). This blood parameter has been proven to re-
late positively with the probability of  developing in-
fections. 1 However other blood parameters, like CD4 
lymphocyte count has also been proven to positively 
correlate with the tendency to develop opportunistic 
and life threatening infections. Some studies in cancer 
patients on chemotherapy have shown that those that 
develop marked CD4 lymphopaenia (< 450 cells/μL) 
have increased mortality irrespective of  their absolute 
neutrophil count.2,3 Normal reference value for CD4+T 
lymphocyte count in the Caucasian population is 400 
– 1500 cells/µL, while a mean absolute CD4 count of  
665.6 ± 246.8 and 95% confidence interval (C.I) 588.7 
– 742.5 cells/µL were obtained in a Tanzanian study of  
which majority were blacks.4 However studies done in 
Nigeria reported a mean CD4+T lymphocyte count of  
830 cells/µL, with a range of  514 – 1207 cells/µ1, in 
healthy adult.5
Several studies have shown that individuals of  African 
descent have lower total white cell and ANC compared 
to Caucasians.6 The accepted neutropaenic threshold of  
1.5 x 109/L is therefore obviously not appropriate for 
people of  negroid descent whose lower reference limit 
is ANC 1.3 x 109/L.6,7 Neutropenia remains the most 
common predisposing factor to infections in cancer pa-
tients.1,8,9 The accepted definition of  neutropenia is an 
absolute neutrophil count ≤ 1.5 x 109/L,8 though in our 
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environment with observed lower absolute neutrophil 
counts, a value of  1.2 x 109/L may be considered, be-
ing the lower limit of  our reference range. Therefore 
the use of  a different or an additional parameter maybe 
required to actually discern those who are actually im-
mune-suppressed in this group.
This study therefore aims to examine the changes that 
occur in absolute neutrophil and CD4 lymphocyte 
count in cancer patients due to disease and or due to 
chemotherapy. It will also try to compare the changes 
in these parameters for the different types of  cancer as 
well as various chemotherapeutic regimens, and possi-
bly detect the most immunotoxic combinations.
Methods
The incidence of  cancer patients in adults in Universi-
ty of  Nigeria teaching hospital (UNTH) Enugu from 
January to December 2007, was calculated to be 0.052, 
using data obtained from the hospital cancer registry to 
obtain a sample size of  76 (approximated to 80). This 
was a prospective analysis of  eighty adult cancer pa-
tients who were assessed in a cross-sectional manner. 
The patients had histologically diagnosed malignan-
cies, and were treated with cytotoxic chemotherapeu-
tic agents. They were recruited in a non-randomized 
consecutive sampling pattern. Patients, who had been 
exposed to any form of  cytotoxic therapy or had been 
diagnosed with any infection, were excluded from the 
study.CD4 positive lymphocyte count and absolute neu-
trophil count was carried out on all respondents who 
gave informed consent, on days 0 and 12 of  the first 
cycle. Day 12 was chosen because this was the known 
neutrophil nadir for most cytotoxic chemotherapeutic 
agents. The CD4 lymphocyte count was obtained using 
an automated Partec Cyflow® 2000 CD4 cell counter, 
while the absolute leucocyte count was obtained using 
an automated 5-part differential Mythic 22 haematology 
analyzer. The socio- demographic data of  the patients 
was assessed from a questionnaire. Ethical approval was 
obtained from the UNTH health research and ethics 
review board.
Data obtained in this study was analyzed using statistical 
package for social sciences (SPSS) 17.0; frequency dis-
tribution data was generated for the different variable 
responses and displayed as tables and figures. Krusk-
er-Wallis normality test was carried out prior to analysis 
and normal distribution was observed in patients age, 
ANC and CD4 counts.  Inferential analysis was done 
using the Paired sample t -Test and significant p value 
was set at P < 0.05, with a 95% confidence interval.
Hypothesis
This study hypothesizes that CD4 lymphocyte count is 
a more sensitive marker of  immunosuppression due to 
cytotoxic chemotherapy, than ANC which is being rou-
tinely used.
Results
The mean ANC pre-and post-chemotherapy were 
3.7±2.2 x 109/L and 2.5±1.6 x 109/L (p= 0.01). The mean 
CD4 lymphocyte count obtained pre-and post-chemo-
therapy were 594±357 cells/µL and 412±224 cells/µL 
(p=0.01). There were significant differences in both the 
ANC and CD4 lymphocyte counts after chemotherapy 
compared to the pre-chemotherapy values.
The mean pre-chemotherapy ANC for males was  3.8± 
2.3 x 109/L and 3.7 ± 2.1 x 109/L for females, while 
the mean pre-chemotherapy CD4 lymphocyte count 
was 534± 326 cells/µL for males and 625 ± 371 cells/ 
µL for females. The mean post-chemotherapy ANC for 
males was 2.7± 2.1 x 109/L and 2.4± 1.3 x 109/L for 
females, while their CD4 counts were 364 ± 175 cells/ 
µL for males and 436± 243 cells/ µL for females, post 
–chemotherapy.




Parameter Day 0+STD Day 12 + STD t- Test (p value) 
1.Ca Breast 36 ANC (x 109/L) 3.577 + 2.340 2.326 + 1.500 3.436(p<0.01)* 
 CD4 (cells/µL) 612.97 +329.17 428.06 +239.17 5.782(p<0.001)* 
2.NHL 8 ANC (x 109/L) 3.650+ 2.646 2.088±0.640 2.045 (p =0.08) 
CD4 (cells / µL) 642.00+261.19 513.50+272.51 2.460(p=0.04)* 
3.Hodgkin’s 
Lymphoma 
13 ANC (x 109/L) 3.700+2.357 2.729+ 2.729 1.359 (p = 0.20) 
CD4 (cells/ µL) 501.54+ 441.90 351.46+ 190.53 1.766 (p =0.10) 
4.Multiple 
Myeloma 
7 ANC (x 109/L) 4.000+1.780 2.114+ 0.780 3.770(p = 0.01)* 
CD4 (cells/µL) 566.00+439.04 410.43+ 177.75 0.993 (p = 0.36) 
5.Colorectal 
Ca 
6 ANC (x109/L) 3.817+ 1.508 3.250+ 1.060 1.619 (p=0.17) 
CD4 (cells/µL) 641.83+ 325.17 374.50+ 189.30 2.818 (p = 0.04)* 
6. Ca Cervix                   1                                                   NOT APPLICABLE 
7. Other 
Cancer 
 9 ANC (x 109/L) 3.778+ 1.651 2.711+ 1.657 2.131 (p = 0.07) 
CD4 (cells/µL) 524.89 + 376.09 324.00+ 180.11 2.635(p= 0.030)* 
* Statistically Significant, p < 0.05 
      STD = Standard Deviation; Freq = Frequency: ANC = absolute neutrophil count 
       CD4 = CD4 positive lymphocyte count 
        Ca = Cancer; NHL = Non –Hodgkin’s Lymphoma 
In all 36/80 (45%) cases of  breast cancer were seen. 
The patients’ ages ranged from 26-69 years with a mean 
age of  48 years, and this consisted of  35/36 (97%) fe-
males and 1/36 (3%) male patient. Most of  the patients 
(58.3%) presented with advanced disease, while 15/36 
(41.7%) of  them presented with the early stage of  the 
disease. 
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Table 2: Observed Mean ANC and CD4 counts with different Cytotoxic Regimen 




Day 0 + STD Day 12+ STD t –Test (p value) 
1.(C&A) 30 ANC 3.757+ 2.431 2.352+1.585 3.633(p <0.001)* 
CD4 621.70+ 374.33 442.70+ 255.26 5.083 (p <0.001) 
2. C &A + 
Cisplatin 
4 ANC 3.600 + 0.990 2.100 + 0.707 1.250 (p=  0.43) 
CD4 668.00 ± 178.19 271.50 ± 6.36 3.263 (p =0.19) 
3. CHOP 6 ANC 2.840 ± 1.552 1.860±  279.65 1.850 (p = 0.14) 
CD4 728.20 ± 287.37 584.00± 279.65 1.850(p =0.14) 
4. C & Epirubicin 3 ANC 2.700±  1.697 2.800± 0.424 -0.067 (p= 0.96) 
CD4 665.50± 169.00 280.50± 53.03 2.452(p = 0.96)  
5. COPP 6 ANC 4250± 2.089 4.083± 3.647 0.144(p =0.89) 
CD4 378.00± 189.83 261.67± 133.98 2.828(p =0.04)* 
6. C & A + 5-FU 3 ANC 3.880± 3.705 1.195± 1.563 0.721(p = 0.60) 
CD4 942.50± 300.52 623.00± 42.43 1.751(p=0.33) 
7. ABVD 7 ANC 2.950 ± 2.765 1.547± 0.696 1.418(p=0.22) 
CD4 452.50± 443.85 352.17± 48.49 0.613(p = 0.567) 
8. M&P 4 ANC 3.167± 1.914 1.633 ±0.513 1.403 (p = 0.3) 
CD4 536.00 ± 151.09 503.67± 176.47 0.462(p=0.69) 
9. C,Mtx & 5-FU 5 ANC 2.550± 0.495 1.850 ± 0.919 2.333(p = 0.26) 
CD4 538.50± 293.45 467.50± 408.00 0.877(p =0.54) 
10. M,P &T. 3 ANC 4.100. ± 2.263 2.100 ± 0.707 1.818 (p = 0.32) 
CD4 948.50± 755.90 452.50± 65.76 0.854(p = 0.55) 
11. FCA 5 ANC 3.750 ± 1.863 2.900± 1.236 2.142 (p =0.12) 
CD4 605.75 ±361.84 304.50± 89.44 1.915(p= 0.15) 
12. Others 4 ANC 4.288 ± 2.189 2.935 ± 1.269 2.973(p < 0.01)* 
CD4 527.82 ± 374.54 380.29 ± 224.36 3.048 (p =<0.01)* 
*Statistically Significant, (p < 0.05) 
C = Cyclophosphamide; M = Melphalan; P = Prednisolone; Mtx = Methotrexate 
T = Thalidomide; FAC = 5 –FU, Adriamcyin, Cisplatin; 5-FU = 5-Fluorouaracil; 
C = Cyclophosphamide; O = Oncovin (Vincristine); P = Procarbazine; A = Adriamcyin 
H = Hydroxodaunorubicin; P = Prednisolone; B = Bleomycin; V = Vinblastine; D = Dacarbazine 
Eight (8/80) (10%) of  the patients had non-Hodgkins 
lymphoma (NHL), 6/8 (75%) of  these were males 
while 2/8 (25%) were females and their ages ranged 
from 18-67 and a mean age of  39.13 years. Six (75%) 
of  the patients presented with the early stages of  the 
disease (stage I & II), while 2/8 (25%) presented with 
the later stages of  the disease. 
Thirteen 13/80 (16.25%) of  the cases had hodgkin’s 
lymphoma, aged 18-65 years with a mean age of  38 
years. Of  these 9/13 (69.2%) presented with the early 
stages of  the disease, while 4/13(30.8%) had the ad-
vanced stages of  the disease. Seven (53.8%) of  them 
were males while 6/13(46.2%) were females.
In all, 7/80 (8.75%) of  the patients had multiple myelo-
ma, of  whom 4/7(57.1%) were males and 3/7 (42.9%) 
were females. Their ages ranged from 31 – 75years, 
with a median age of  58 years. Majority of  the patients, 
6/7 (85.7%) presented with advanced disease (Durie 
&Salmon stage III or IIb), while only one patient had 
early disease. There was a total of  6/80 with colorectal  
ca (7.5% patients in all, 3/6 (50%) males and 3/6 (50%) 
females. Their ages ranged from 32-80 years, with a me-
dian age of  46 years, and 4/6 (66.7%) had early disease, 
while 2/6 (33.3%) had late disease. Only one case of  ca 
was seen in a 48 year old woman, who had a pre-and 
post - chemotherapy ANC of  7.8 x 109/L and 3.9 x 
109/L respectively, and CD4 count of  1258 cells/ µL 
and 805 cells/ µL, respectively. For this single outcome 
the test for statistical significance could not be applied. 
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Figure 2: Age and gender distribution of  respondents
Discussion
In this study the patients were mainly adults between 18 
and 80 years, with a median age incidence of  45 years. 
This supports the general knowledge that malignancies 
can occur in any age group. It is however noteworthy 
that the population used in this study is not representa-
tive of  the overall cancer population in adults patients, 
since only patients whose malignancies were amenable 
to chemotherapy were recruited. However a compar-
ison of  the changes observed in absolute neutrophil 
count to that of  the CD4 lymphocyte count can still be 
deduced from the result of  this study. Majority of  the 
affected patients were females (66.3%), this is similar to 
the data on sub-Saharan Africa from the World cancer 5 
year prevalence study10, but data from the study done by 
Borg & Ray- Coquard et al had more of  males (56%).2 
This was probably due to the proportion of  breast can-
cer patients recruited, as this has been noted to be the 
most prevalent cancer in most studies in adults.
The most common malignancy treated with chemo-
therapy according to this study was breast cancer, this 
is known to be most common malignancy in women in 
Nigeria, while for the males the most common is car-
cinoma of  the prostate. This is supported by the study 
done by Ojo et al, in Parkins data on the West African 
sub-region,11 for international agency for research on 
cancer in collaboration with WHO and Adelusola KA 
in South West Nigeria.12 Hodgkin’s lymphoma was the 
second most prevalent malignancy in this study; how-
ever this is not supported by any previous cancer prev-
alence study, and is most likely attributable to the fact 
that not all cancer patients were recruited in this study, 
but only those who were booked for chemotherapy. 
Also other more common malignancies noted in other 
cancer prevalence studies, like cancer of  the cervix and 
prostate were not usually treated with chemotherapy in 
their early stages. Non-Hodgkin’s lymphoma was the 
third most common malignancy in this study and this 
is supported by findings of  other studies in adult pop-
ulations in Nigeria.10 About half  of  the patients in this 
study presented with early stages of  their malignancies, 
this not supported by the finding of  Borg’s group in 
cancer patients in France,2 where more than 65% of  the 
patients presented with advanced disease.
The mean values of  neutrophil and CD4 lymphocytes 
recorded before and after chemotherapy in this study 
was found to be 3.7and 2.5 x 109/L; 594 and 412 cells/
µL, respectively which were all within the normal refer-
ence ranges for Nigerians except the day 12 CD4 lym-
phocyte count. The changes in these parameters from 
the pre-chemotherapy values were both statistically sig-
nificant. This is similar to the findings of  Khan et al in 
his study on solid tumours,13 and may be an indicator 
that the CD4 count is a more appropriate index of  im-
munosuppression within the first few days post-chemo-
therapy.
In breast cancer patients mean absolute neutrophil 
counts pre-and post-chemotherapy were both with the 
normal reference range for Nigerians. This is similar to 
the results obtained in studies by Silber et al who ob-
served a first cycle of  ANC nadir of  2.1 - 9.2 x 109/L, 
14 and another study done by Rivera et al who obtained 
values of  2.3 - 9.9x109/L.15 Studies done in Negros in 
Africa had revealed lower neutrophil counts and this 
has been shown to be also true for black population 
elsewhere.6,7,16 Worthy of  note also is the fact that Ezei-
lo deduced from his study that neutropenia in Africans 
was non-genetic, but this was contrary to observations 
by Hershman et al,of  neutropenia in African American 
females.6,16 However the change in absolute neutrophil 
count in these patients was found to be significant, as 
had been seen in previous studies. The pre-chemother-
apy mean CD4 count was within normal adult reference 
values, but this dropped to a significantly lower value 
post-chemotherapy, as has been noted in other studies. 
Lymphomas have been shown to have additional im-
munosuppressive effects in affected patients; this may 
be greater on the humoral than the cellular aspect of  
patients’ immune system which this study is focused 
on. The change in CD4 lymphocyte count in these 
patients was found to be significant (p=0.043). Most 
of  the patients in this group received cyclophospha-
mide, hydroxodaunorubicin, oncovin and prednisolone 
(CHOP) chemotherapy, which contained cyclophos-
phamide and daunorubicin. In the study done by Mack-
all et al significant depreciation of  both the ANC and 
CD4 counts were observed, however the NHL patients 
in this study received higher doses of  chemotherapy 
(cyclophosphamide 1.6g/m2, doxorubicin 40mg/m2, 
methotrexate 6.72g/m2 and vincristine 1.5mg/m2).3 
Though in these studies a low baseline CD4 count was 
recorded, which was not supported by our study. How-
ever we noted again that amongst patients with NHL 
the CD4 count was a better and more suitable marker 
of  immunosuppression than the ANC, showing a sig-
nificant change of  p< 0.05. Individuals with Hodgkin’s 
lymphoma in this study had normal baseline mean CD4 
counts as previous studies had shown. This was more 
in the patient group who received cyclophosphamide, 
oncovin, procarbazine, prednisolone(COPP), and less-
er with the patients who were given adriamycin, bleo-
mycin, vinblastine and darcabazine (ABVD). Previous 
reports show that ABVD is less toxic to the gonads, 
and thus cause less infertility than COPP, findings of  
this study however suggests that it may actually be less 
immunotoxic. This may be due to the 14 day treatment 
with oral procarbazine compared to the single parenter-
al dose of  dacarbazine. 
In patients diagnosed with multiple myeloma, only the 
change in ANC was significant and the day 12 ANC 
was lower than the Caucasian reference values, but still 
within the normal reference range in Nigerians. The 
mean pre-chemotherapy ANC and CD4 counts were 
within normal range, this is similar to the findings by 
Borg’s group, who recorded a median CD4 counts of  
650 cells/µL and ANC of  5.1 x 109/L.2 However in this 
study melphalan –based combinations were used for 
majority of  the patients, while in Borg study other dexa-
methasone-base combinations were preferred. Though 
similar outcomes were recorded in both studies, it must 
be noted that in Borgs study some of  the patients had 
been exposed to previous chemotherapeutic treatment 
and the pre-chemotherapy values were assessed on day 
5 of  the cycle.
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The other malignancies recorded were ovarian carci-
noma, serminomas, osteosarcoma, malignant fibrous 
histiocytoma, liposarcoma, squamous cell carcinoma 
and cancers of  the larynx, stomach, urinary bladder, 
and rhabdomyosarcomas. These malignancies were less 
frequently seen, each contributing less than 3% of  all 
cases seen. This category consisted of  9/80 (11.25%) 
of  the patients, their ages ranged from 25-72 years, with 
a median age of  44 years. Five 5/9 (55.6%) of  the pa-
tients presented with early disease, while 4/9 (44.4%) 
had advanced cancers.
Only one patient with cervical cancer was recruited into 
this group, this low rate may be attributable to the pref-
erence for other modes of  treatment, mostly radiother-
apy and surgery. Use of  cytotoxic chemotherapeutic 
agents is usually reserved for the very advanced cases; 
the outcome from this group was therefore too few to 
be analyzed. 
The pre-chemotherapy mean CD4 count in patients 
with other malignancies was the second lowest, after 
Hodgkin’s lymphoma, also the change in this parame-
ter was found to be significant. The individuals in this 
group had a wide variety of  malignancies viz; osteosar-
coma, liposarcoma, squamous cell carcinoma, histiocy-
toma, seminoma, as well as cancer of  the larynx, ova-
ries, stomach and urinary bladder. However the change 
in blood parameters within each patient, irrespective of  
the differences between individual patients (in terms 
of  diagnosis of  chemotherapy regimen used) is still a 
worthy indicator of  the degree of  immunosuppression 
in each group of  patients. These patients also received 
a wider variety of  drugs compared to other groups; 
though both parameters were depressed as expected the 
CD4 count proved to be more sensitive of  the immu-
nosuppressive effect of  these drugs.
The CD4 lymphocyte was generally was found to be-
significantly reduced in more patient groups than the 
ANC, and this may be an indication of  the suitability of  
this parameter.
Effects of  different chemotherapeutic agents on 
ANC and CD4 Count   
The patients in this study were exposed to a wide range 
of  cytotoxic drugs based on their various diagnoses. 
However some of  these individuals with similar diag-
nosis in some instances received different chemothera-
peutic regimen. The differences in regimen given were 
based on the stage of  the disease or its aggressiveness, 
age of  the patient, presence of  other co-morbidities, 
or performance status, as well as the individual biases 
of  the managing team. This has offered an, albeit less 
than ideal, opportunity to compare the extent of  immu-
nosuppression caused by these various combinations, 
and perhaps an opportunity to identify some “worse 
offending” drugs or combinations. However as previ-
ously noted the change in each of  these immunological 
parameters within each individual still remains a valid 
means of  comparison irrespective of  the differences 
in chemotherapeutic agents used. Single agent cancer 
chemotherapy is rarely practiced and ethical issues limit 
studies of  this kind with respect to isolating the individ-
ual effect of  these drugs.
The patients who received cyclophosphamide and adri-
amycin showed changes in both their mean ANC and 
CD4 counts, however only the ANC was significantly 
reduced. The dose of  adriamycin in this regimen was 
50mg/m2, as opposed to the dose in ABVD which is 
25mg/m2, which seemed to cause less immuno-toxicity. 
This is similar to the findings of  Borg et al where the 
doses of  some of  the drugs rather than the individual 
agents themselves were found to be the causative factor. 
Doses of  Adriamycin in excess of  90mg/m2 or cyclo-
phosphamide ≥ 1g/m2 per course have been implicated 
as a cause of  immunosuppression.15
Other chemotherapeutic agents used were basically for 
less frequent malignancies, advanced or aggressive dis-
ease. These combinations are generally thought to be as 
toxic as they are potent and it is therefore not surprising 
that they significantly lower the ANC and CD4 counts 
as found in this study.
Conclusion
This study confirms that anti-cancer chemotherapy 
causes significant depletion of  neutrophils as well as 
CD4 lymphocytes in adults with malignancies. Howev-
er we observed that CD4 lymphocyte count are deplet-
ed more significantly, than ANC in patients diagnosed 
with several malignancies. Also COPP seems to cause 
more significant CD4 depletion than other combina-
tions used to treat lymphoma. This may be of  more 
importance in people of  Negroid descent with a lower 
baseline ANC. It may be necessary to embark on a more 
elaborate and extensive study in order to determine the 
authenticity of  these findings in larger patient group.
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